Previous 10 | Next 10 |
2024-07-12 16:55:48 ET More on Eli Lilly What Eli Lilly Is Getting With The Acquisition Of Morphic Holding Wall Street Lunch: Merger Monday In All Its Glory Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal These are the weight loss drug...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 12:30:05 ET UBS analyst issues BUY recommendation for LLY on July 12, 2024 10:21AM ET. The previous analyst recommendation was Buy. LLY was trading at $946.69 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst reco...
2024-07-12 12:15:26 ET More on ChargePoint Holdings, Tupperware ChargePoint: A Contrarian EV Play For Growth Investors ChargePoint: Struggles Remain Persistent ChargePoint's Management Is Too Optimistic About The Future ChargePoint appoints Mansi Khetani CFO ...
2024-07-12 11:30:00 ET Summary The Headwaters Capital Management portfolio returned +1.3% (+1.1% net) during Q2 2024 compared to a -3.4% decline for the Russell Mid Cap Index over the same period. Outside of the macro narratives that impacted the market, the AI theme continues to ...
2024-07-12 10:50:24 ET Read the full article on Seeking Alpha For further details see: These are the weight loss drug stocks with the most upside - SA Sentiment Survey
2024-07-12 10:27:31 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk once-weekly insulin rejected by FDA ...
2024-07-12 06:13:00 ET "Winners keep winning." Whatever one thinks of this adage, it certainly seems to apply to Eli Lilly (NYSE: LLY) . The pharmaceutical giant has been on a tear, racking up important clinical and regulatory victories in the past few years. The result: Eli Lilly h...
2024-07-12 04:12:28 ET More on Amgen Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade) Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum Amgen: You Haven't Seen Anything Yet Lilly, Novo Nordisk to dominate weight lo...
2024-07-11 14:19:51 ET Summary Pfizer Inc. announced today that it planned to continue development of its GLP-1 agonist weight loss drug danuglipron as a once-daily oral pill. The drug met efficacy endpoints in a Phase 2 study last year as a twice daily pill, but side effects caus...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 07:15:00 ET According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't. Equities that can perform well throughout bull runs might be good to ...
2024-07-26 07:45:00 ET Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. Outside of the technology industry, investors have also foun...
2024-07-25 19:06:06 ET It wasn't so long ago when Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks were flying high thanks to their hotly popular weight loss drugs (Wegovy/Ozempic for Novo Nordisk and Zepbound/Mounjaro for Lilly). In the pharmaceutical industry,...